about
Treatment of Cushing disease: overview and recent findingsThe effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegalyPlace of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysisMeta-analysis on the effects of octreotide on tumor mass in acromegalyMetabolic glucose status and pituitary pathology portend therapeutic outcomes in acromegaly.Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas.Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review.Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly.Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guidelineExpert consensus document: A consensus on the medical treatment of acromegaly.Surgical management of acromegaly in a resource-challenged environment.Acromegaly with cardiomyopathy, cardiac thrombus and hemorrhagic cerebral infarct: a case report of therapeutic dilemma with review of literature.Results of gamma knife radiosurgery in acromegaly.A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly.The association between biochemical control and cardiovascular risk factors in acromegaly.Changing paradigms in the surgical and medical management of acromegaly.The multimodal management of GH-secreting pituitary adenomas: predictive factors, strategies and outcomesFrom somatostatin to octreotide LAR: evolution of a somatostatin analogueCost of management of invasive growth hormone-secreting macroadenoma.A survey of clinical practice patterns in diagnosis and management of Cushing's disease in Iran.Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly.Excess mortality in acromegaly.Somatostatin agonists for treatment of acromegaly.A consensus on the diagnosis and treatment of acromegaly complications.Risperidone-induced acromegaly: a case reportGrowth hormone excess and the development of growth hormone receptor antagonists.Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults.The management of the patient with acromegaly and headache: a still open clinical challenge.Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly.Pituitary adenomas in childhood and adolescence with a focus on intratumoral hemorrhage.Pharmacokinetic evaluation of lanreotide.Acromegaly surgery in Manchester revisited--the impact of reducing surgeon numbers and the 2010 consensus guidelines for disease remission.Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors.What is active acromegaly and which parameters do we have?Estrogen and selective estrogen receptor modulators (SERMs) for the treatment of acromegaly: a meta-analysis of published observational studies.Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors.Management of aggressive growth hormone secreting pituitary adenomas.Primary treatment of acromegaly with high-dose lanreotide: a case series.Current management practices for acromegaly: an international survey.Long-term results of fractionated stereotactic radiotherapy as third-line treatment in acromegaly.
P2860
Q24626819-50BEF488-92F5-4224-90AC-63306F25D406Q26796357-276ABEB5-B34A-4FFC-B22C-399B5E93E7FCQ27693237-910CB62D-031D-4A5C-A70F-58E4EE5FC94BQ28730120-329295CF-FE7D-48F4-B24B-74C670BF5DECQ31139308-8A2672DF-4246-49AD-BE62-7AE4098065CEQ33579615-AA018797-8FE4-44D1-904F-350200C38A32Q33772673-0BAAA442-BE99-44B0-ABD2-D17276B2DE4EQ33794409-8F767874-4EBF-4D04-A329-56FFBAEE916BQ34277844-2400217B-28CE-4AE1-8636-04D01A6B4642Q34406566-74670541-646A-444B-A428-956D37940248Q35041686-9719B62F-604D-497A-8327-40DEE82BD44DQ35428187-4DB8A2A0-4A89-45F1-B372-08B93506364FQ35810478-481E8458-6CA4-4634-BDFD-99B6B1527FA0Q35987499-D4180B6B-0290-43B2-A3AA-F274E9EF1988Q36303177-5745D4C8-2CF5-4C02-A39A-CBD6AED1E28BQ36605363-6FBBDD6C-AFBD-427F-90D7-EB397361B475Q36890994-58CFCE9C-E0A0-40F9-BD1B-1CE597A1CC1EQ36919554-5221F578-8BEE-456B-B62C-ABC665316CF3Q36937812-C00C4B70-D2B4-487A-A624-3D4508CC2746Q36983219-652127E9-6E4C-4422-B753-C7EA4967BEDDQ37029532-EFB8F975-4103-4D1A-B278-5779C2C4A3C6Q37050111-931272FB-94D9-4B52-AE57-993F09095205Q37055643-7CD74E52-6309-4894-8D32-EEF93EAF530AQ37061155-A2BD46AE-4183-4D51-900B-B01C3284C53BQ37079013-A6DD494A-E5A4-4C17-9F21-8F8051A1EC57Q37212629-AEC75D52-CF24-4A16-A5E2-C02AA59EA42EQ37321948-270000D3-8A22-4C33-9B9D-AAB1E5A86404Q37353632-F3DA1706-2FCA-4DD6-B76B-1E13A84F23CBQ37519612-EF174B6F-255F-4F5A-B131-C156675D1B5BQ37531036-47FC5F2B-1C38-4760-8CB0-DD849DEACCFFQ37780553-22ACA244-D61C-4C3E-AC6A-3545F1D29134Q37913480-F4DA07A3-253D-4DA1-B8FB-4F169B144924Q37941521-E151E927-8116-479A-8390-DE8834A54ED4Q37977989-87CEB495-8ADA-4C15-812F-05441007A9EFQ38127391-D31C0D36-6F99-4842-9EE8-BBF4D5956170Q38233686-EE2D14F7-0006-4BFA-B0E6-86273D771ED7Q38781620-32251D27-B7D6-4CA7-B24A-07BBF70F60DCQ39787141-F28EAE2F-17C3-4C40-ADF6-39ACC1AE80FFQ39818772-ECA8E3C3-4B65-4244-A48D-143A08060FCFQ40959314-D97F559C-E7EC-497E-8316-95BD08744B65
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Consensus statement: medical management of acromegaly.
@ast
Consensus statement: medical management of acromegaly.
@en
type
label
Consensus statement: medical management of acromegaly.
@ast
Consensus statement: medical management of acromegaly.
@en
prefLabel
Consensus statement: medical management of acromegaly.
@ast
Consensus statement: medical management of acromegaly.
@en
P2093
P356
P1476
Consensus statement: medical management of acromegaly.
@en
P2093
A Giustina
D Kleinberg
F Casanueva
F Cavagnini
G Lombardi
J A H Wass
L A Frohman
P304
P356
10.1530/EJE.1.02036
P577
2005-12-01T00:00:00Z